New York, May 21, 2025 (Globe Newswire) – Complement 1A pioneer company of health technology transforming care against cancer thanks to a modification of the lifestyle based on evidence, announced today the appointment of Dr Christopher Cogle as a new chief doctor (CMO). Dr. Cogle, a distinguished oncologist, translational researcher and director of health, joins complement 1 while the company accelerates clinical validation and the scale of its personalized life-style life intervention platform after its recent $ 16 million in seed financing.
Dr. Cogle brings with him a wide experience in innovation of oncology, clinical research and health policy. He is an oncologist and professor at the University of Florida, where he led translational research initiatives and revolutionary clinical trials that have advanced new therapies for blood cancers. His pioneer research has enlightened the global protocols in cancer treatment and led to several dedicated companies dedicated to innovative treatments in oncology.
“Cancer patients face questions that change life like” What should I eat? ” How should I move? How to find peace? However, they are often left to understand him alone, “said Dr. Cogle. “The complement 1 reduces this gap with a coaching supported by science that meets patients where they are, every day. I am delighted to direct our clinical strategy to show that changing life habits is not only good advice – it is a good medication.”
The complement 1 platform is specially designed for cancer patients, offering personalized daily support thanks to its coactive coaching model. Unlike traditional programs that only offer occasional checks, complement 1 provides individual coaching every day, anchored in clinically proven behavioral change methods. The result is an average membership rate of 90% which establishes a new standard for patient engagement.
The coactive coaching program takes place on a medically validated validated rules which adapts life -style life to the type of specific cancer, the treatment stage, the side effect profile and the personal objectives of each patient. The first clinical trials show that this precision approach can considerably reduce side effects of treatment, improve sleep, facilitate pain and improve the overall quality of life of people with cancer.
“The appointment of Dr. Cogle as a chief doctor marks an important step for complement 1,” said Trupti Mukker, head of the exploitation and co-founder of complement 1. “He is not only a doctor and a cancer scientist recognized on a national level, he is a proven leader who knows how the intersection of science, medicine and politics. really experience.
As CMO, Dr. Cogle will focus on the validation and widening of the evidence of supplement 1. It will guide the current and future clinical trials, will refine the medical strategy of the company and engage with health care providers and institutions to integrate lifestyle medicine into standard oncology practices.
Dr. Cogle brings a rare mixture of experience in clinical leadership, research and health system to complement 1. As a sponsor, inventor, researcher and health decision -maker, he worked in the spectrum of care against cancer of the advancement of new therapies in the laboratory and in the clinic to shape the health policy at the level of the state. This unique perspective positions it to help complete 1 a transformative lifestyle medicine solution that meets the needs of patients, providers, health systems and employers.
“I devoted my career to the development of laboratory, clinic and conference room treatment,” added Dr. Cogle. “But treatment alone is not enough. Complement 1 proves that the change in lifestyle, when it is well done, can reduce side effects, improve quality of life and reduce health care costs. It is the future of cancer care, and I am proud to be part of it.”
About complement 1
Complement 1 is a health technology company dedicated to the transformation of cancer care through lifestyle medicine. Founded in 2024, complement 1 has developed the first lifestyle assisted by clinically validated technology with daily coactive coactive 1: 1 for cancer patients, survivors and those at high risk. By combining personalized coaching with interventions based on evidence in physical activity, nutrition and somatic practices, complement 1 helps patients to improve results and quality of life while reducing up to 30% for employers, providers and insurers. Supported by the main oncologists and scientific research, the complement 1 platform fits perfectly into conventional oncology care to provide better results and empower patients in their healing journey. The company has its headquarters in the United States with a mission to make care of cancer accessible to everyone. For more information, visit additional1.com.
Contact with the media
Caroline Statile
Marketing + media scratch for supplement 1
caroline@scratchmm.com
